Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. - Hurvitz SA; Bosserman LD; Chan D; Hagenstad CT; Kass FC; Smith FP; Rodriguez GI; Childs BH; Slamon DJ (SpringerPlus, 2014)